| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 5 days from now) | |
| US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 5 days from now) | |
| US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 5 days from now) | |
| US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 5 days from now) | |
Aemcolo is owned by Redhill.
Aemcolo contains Rifamycin Sodium.
Aemcolo has a total of 4 drug patents out of which 0 drug patents have expired.
Aemcolo was authorised for market use on 16 November, 2018.
Aemcolo is available in tablet, delayed release;oral dosage forms.
Aemcolo can be used as treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults.
Drug patent challenges can be filed against Aemcolo from 17 November, 2027.
The generics of Aemcolo are possible to be released after 16 November, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE;ORAL
AEMCOLO family patents
